Clinical trial · Observational
The Efficacy of Sequential RT After Triple Therapy for uHCC
The Efficacy of Sequential Radiotherapy After the Combination of Transcatheter Arterial Chemoembolization With Lenvatinib and Anti-PD-1 Antibodies for Unresectable Hepatocellular Carcinoma
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Triple therapy of transcatheter arterial chemoembolization (TACE) combined with lenvatinib and anti-PD-1 antibodies has demonstrated excellent efficacy in unresectable hepatocellular carcinoma (uHCC). However, tumor drug resistance is still a major problem and many patients fail to achieve complete necrosis of the lesions after treatment. This study aimed to investigate the efficacy and safety of sequential radiotherapy after triple therapy in patients with uHCC to improve tumor response rate.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hepatocellular Carcinoma | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| sequential radiotherapy after the combination of transcatheter arterial chemoembolization (TACE) combined with lenvatinib and anti-PD-1 antibodies | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- sequential radiotherapy after triple therapy
- description
- Patients with unresectable hepatocellular carcinoma received sequential radiotherapy after the combination of transcatheter arterial chemoembolization with lenvatinib and anti-PD-1 antibodies
- interventionNames
- Drug: sequential radiotherapy after the combination of transcatheter arterial chemoembolization (TACE) combined with lenvatinib and anti-PD-1 antibodies
Primary outcomes (1)
- measure
- OS
- timeFrame
- From date of randomization until the date of date of death from any cause or the most recent follow-up, whichever came first, assessed up to 100 months
- description
- overall survival
Secondary outcomes (2)
- measure
- PFS
- timeFrame
- From date of randomization until the date of first documented progression, the date of death from any cause or the date of most recent follow-up, whichever came first, assessed up to 100 months
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * Patients diagnosed with HCC and assessed as unresectable by multidisciplinary team (MDT) * Patients who achieved PR or SD after triple therapy according to the mRECIST and did not meet the criteria for radical surgical resection or could not tolerate surgical treatment * Patients who received sequential radiotherapy * Age between 18 and 75 years * Child-Pugh class A or B * Eastern Cooperative Oncology Group performance status (ECOG PS) score of 0-1 Exclusion Criteria: * Previous acceptance of other antitumor treatments * Treatment in conjunction with other treatment regimens, such as radiofrequency ablation and chemotherapy * History of other malignancies * Incomplete data.
References
Publications (0)
Data not yet available